TW586936B - Adjuvant composition, vaccine composition, process for manufacture thereof and kit comprising same - Google Patents
Adjuvant composition, vaccine composition, process for manufacture thereof and kit comprising same Download PDFInfo
- Publication number
- TW586936B TW586936B TW088117873A TW88117873A TW586936B TW 586936 B TW586936 B TW 586936B TW 088117873 A TW088117873 A TW 088117873A TW 88117873 A TW88117873 A TW 88117873A TW 586936 B TW586936 B TW 586936B
- Authority
- TW
- Taiwan
- Prior art keywords
- antigen
- virus
- vaccine composition
- metal salt
- patent application
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000002671 adjuvant Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 54
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 230000008569 process Effects 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims abstract description 132
- 102000036639 antigens Human genes 0.000 claims abstract description 132
- 108091007433 antigens Proteins 0.000 claims abstract description 132
- 239000002245 particle Substances 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 229910052751 metal Inorganic materials 0.000 claims abstract description 37
- 239000002184 metal Substances 0.000 claims abstract description 37
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 27
- 229960001438 immunostimulant agent Drugs 0.000 claims abstract description 24
- 239000003022 immunostimulating agent Substances 0.000 claims abstract description 22
- 241000700605 Viruses Species 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 241000701806 Human papillomavirus Species 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000005252 hepatitis A Diseases 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 208000002672 hepatitis B Diseases 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 7
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 5
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 5
- 241000223996 Toxoplasma Species 0.000 claims description 5
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 238000012737 microarray-based gene expression Methods 0.000 claims description 5
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 201000006082 Chickenpox Diseases 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 241000224016 Plasmodium Species 0.000 claims description 4
- 206010046980 Varicella Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 3
- 241000588807 Bordetella Species 0.000 claims description 3
- 241000589968 Borrelia Species 0.000 claims description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- 208000016604 Lyme disease Diseases 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 102000036673 PRAME Human genes 0.000 claims description 3
- 108060006580 PRAME Proteins 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 201000010284 hepatitis E Diseases 0.000 claims description 3
- 239000002923 metal particle Substances 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052716 thallium Inorganic materials 0.000 claims description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- 229910052790 beryllium Inorganic materials 0.000 claims 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 45
- 239000007853 buffer solution Substances 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 13
- 101710188053 Protein D Proteins 0.000 description 13
- 101710132893 Resolvase Proteins 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 230000002079 cooperative effect Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 208000006454 hepatitis Diseases 0.000 description 11
- 231100000283 hepatitis Toxicity 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 108700006640 OspA Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 201000005702 Pertussis Diseases 0.000 description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- 241000709721 Hepatovirus A Species 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 108700023315 OspC Proteins 0.000 description 4
- 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- -1 GM-CSF and IL-1 Natural products 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 101710137302 Surface antigen S Proteins 0.000 description 3
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 3
- 206010048937 Vaginal lesion Diseases 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 3
- 239000004062 cytokinin Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 241000588780 Bordetella parapertussis Species 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241001647378 Chlamydia psittaci Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 241000605314 Ehrlichia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 101710105759 Major outer membrane porin Proteins 0.000 description 2
- 101710164702 Major outer membrane protein Proteins 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229940029583 inactivated polio vaccine Drugs 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 229940124735 malaria vaccine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 101100162403 Arabidopsis thaliana ALEU gene Proteins 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100030009 Azurocidin Human genes 0.000 description 1
- 101710154607 Azurocidin Proteins 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589978 Borrelia hermsii Species 0.000 description 1
- 241000495356 Borrelia microti Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000142472 Borreliella andersonii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
- WWMNOYQAQAKPEK-UHFFFAOYSA-M C(C)SSC=1C(C(=O)[O-])=CC=CC1.[Na+] Chemical compound C(C)SSC=1C(C(=O)[O-])=CC=CC1.[Na+] WWMNOYQAQAKPEK-UHFFFAOYSA-M 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241001133638 Entamoeba equi Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
- 101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 101710198693 Invasin Proteins 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 101000960966 Mus musculus Interleukin-5 Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- HCUVEUVIUAJXRB-UHFFFAOYSA-N OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC Chemical compound OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC HCUVEUVIUAJXRB-UHFFFAOYSA-N 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
- 101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710132582 Protein D1 Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 1
- 102100031420 Ras-related protein Rap-2a Human genes 0.000 description 1
- 101710203837 Replication-associated protein Proteins 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108010011834 Streptolysins Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 101710134694 Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 101150078331 ama-1 gene Proteins 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008349 antigen-specific humoral response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- WCMJLEULXWUCRF-UHFFFAOYSA-N emarginatoside B Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WCMJLEULXWUCRF-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9822703.6A GB9822703D0 (en) | 1998-10-16 | 1998-10-16 | Vaccine |
| GBGB9822709.3A GB9822709D0 (en) | 1998-10-16 | 1998-10-16 | Vaccine |
| GBGB9822712.7A GB9822712D0 (en) | 1998-10-16 | 1998-10-16 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW586936B true TW586936B (en) | 2004-05-11 |
Family
ID=27269522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW088117873A TW586936B (en) | 1998-10-16 | 1999-10-15 | Adjuvant composition, vaccine composition, process for manufacture thereof and kit comprising same |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7357936B1 (enExample) |
| EP (5) | EP1666060A1 (enExample) |
| JP (3) | JP2003519084A (enExample) |
| KR (1) | KR100629028B1 (enExample) |
| CN (3) | CN100406060C (enExample) |
| AR (1) | AR020836A1 (enExample) |
| AT (1) | ATE357252T1 (enExample) |
| AU (1) | AU750587B2 (enExample) |
| BR (1) | BRPI9915545B8 (enExample) |
| CA (2) | CA2347099C (enExample) |
| CO (1) | CO5210894A1 (enExample) |
| CY (2) | CY1106596T1 (enExample) |
| CZ (1) | CZ301212B6 (enExample) |
| DE (2) | DE122007000087I1 (enExample) |
| DK (1) | DK1126876T3 (enExample) |
| ES (1) | ES2284287T3 (enExample) |
| FR (1) | FR07C0064I1 (enExample) |
| HK (1) | HK1038695B (enExample) |
| HU (2) | HU228473B1 (enExample) |
| IL (2) | IL142395A0 (enExample) |
| LU (1) | LU91389I2 (enExample) |
| MY (1) | MY124689A (enExample) |
| NL (1) | NL300311I2 (enExample) |
| NO (1) | NO336250B1 (enExample) |
| NZ (1) | NZ511113A (enExample) |
| PL (1) | PL201482B1 (enExample) |
| PT (1) | PT1126876E (enExample) |
| SI (1) | SI1126876T1 (enExample) |
| TR (1) | TR200101055T2 (enExample) |
| TW (1) | TW586936B (enExample) |
| WO (1) | WO2000023105A2 (enExample) |
Families Citing this family (268)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0909323B1 (en) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Helicobacter pylori bacterioferritin |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| NZ508927A (en) | 1998-05-22 | 2003-12-19 | Ottawa Health Research Inst | Methods and products for inducing mucosal immunity |
| ES2284287T3 (es) * | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP1198249B1 (en) * | 1999-06-29 | 2005-10-19 | GlaxoSmithKline Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
| GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
| US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
| GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| GB0025170D0 (en) * | 2000-10-13 | 2000-11-29 | Smithkline Beecham Biolog | Novel compounds |
| AU1412702A (en) | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
| JP2004535765A (ja) | 2000-12-07 | 2004-12-02 | カイロン コーポレイション | 前立腺癌においてアップレギュレートされた内因性レトロウイルス |
| EP1409533A2 (en) * | 2001-01-26 | 2004-04-21 | Walter Reed Army Institute of Research | Recombinant plasmodium falciparum merozoite protein-1/42 vaccine |
| US7306806B2 (en) | 2001-01-26 | 2007-12-11 | United States Of America As Represented By The Secretary Of The Army | Recombinant P. falciparum merozoite protein-142 vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
| US20030138458A1 (en) | 2001-06-29 | 2003-07-24 | Michael Houghton | HCV E1E2 vaccine compositions |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| EP1531796B1 (en) | 2002-02-20 | 2016-09-28 | GlaxoSmithKline Biologicals SA | Microparticles with adsorbed polypeptide-containing molecules |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| EP1532161B1 (en) | 2002-06-13 | 2012-02-15 | Novartis Vaccines and Diagnostics, Inc. | Vectors for expression of hml-2 polypeptides |
| AU2003254585A1 (en) | 2002-07-24 | 2004-02-16 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
| SI1549338T1 (sl) | 2002-10-11 | 2011-04-29 | Novartis Vaccines & Diagnostic | Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi |
| EP2279746B1 (en) | 2002-11-15 | 2013-10-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
| US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| AU2003299994A1 (en) * | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| KR100692203B1 (ko) * | 2003-01-23 | 2007-03-09 | 제일모직주식회사 | 도광판, 이의 제조 방법, 이를 이용한 백라이트 어셈블리및 이를 이용한 액정표시장치 |
| CN102302776B (zh) | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
| WO2004084938A1 (en) | 2003-03-24 | 2004-10-07 | Intercell Ag | Improved vaccines |
| ES2351489T3 (es) * | 2003-03-24 | 2011-02-07 | Intercell Ag | Vacunas mejoradas. |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| FR2854803B1 (fr) * | 2003-05-16 | 2005-06-24 | Aventis Pasteur | Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal. |
| PT1631264E (pt) | 2003-06-02 | 2009-11-03 | Novartis Vaccines & Diagnostic | Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano |
| CA2532369C (en) | 2003-07-31 | 2016-07-26 | Chiron Corporation | Immunogenic compositions for streptococcus pyogenes |
| US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| WO2005107797A1 (en) | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| AU2005237289B2 (en) | 2004-04-30 | 2011-08-04 | Glaxosmithkline Biologicals S.A. | Meningococcal conjugate vaccination |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| JP4896021B2 (ja) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 呼吸器系病原体ワクチンのためのアルファウイルスベクター |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
| JP2008508320A (ja) | 2004-07-29 | 2008-03-21 | カイロン コーポレイション | Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物 |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| CN101107007B (zh) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗 |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US20090214592A1 (en) * | 2005-02-16 | 2009-08-27 | O'hagan Derek | Adjuvant composition comprising aluminium phosphate and 3D-MPL |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| EP2351772B1 (en) | 2005-02-18 | 2016-07-13 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
| US20090220547A1 (en) * | 2005-08-02 | 2009-09-03 | Novartis Vaccines And Diagnostics Srl | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
| CA2626253A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| BRPI0618254A2 (pt) * | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
| NZ567981A (en) | 2005-11-04 | 2011-10-28 | Novartis Vaccines & Diagnostic | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| US7527801B2 (en) | 2005-11-22 | 2009-05-05 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and Sapovirus antigens |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP2347775B1 (en) | 2005-12-13 | 2020-04-15 | President and Fellows of Harvard College | Scaffolds for cell transplantation |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2007071710A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| ES2796603T3 (es) | 2006-01-27 | 2020-11-27 | Seqirus Uk Ltd | Vacunas contra la gripe que contienen hemaglutinina y proteínas de la matriz |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| US20100068223A1 (en) | 2006-03-24 | 2010-03-18 | Hanno Scheffczik | Storage of Influenza Vaccines Without Refrigeration |
| US20100021503A1 (en) | 2006-03-30 | 2010-01-28 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| WO2007126825A2 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| CN1864749B (zh) * | 2006-04-12 | 2010-10-06 | 成都夸常医学工业有限公司 | 一种药物组合物及制备方法 |
| US9839685B2 (en) * | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
| AU2007263531B2 (en) | 2006-06-29 | 2012-03-15 | J. Craig Venter Institute, Inc. | Polypeptides from neisseria meningitidis |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| US20100166788A1 (en) | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
| EP2066345B1 (en) | 2006-09-11 | 2015-02-25 | Novartis AG | Making influenza virus vaccines without using eggs |
| US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| HUE036180T2 (hu) | 2006-09-26 | 2018-06-28 | Infectious Disease Res Inst | Szintetikus adjuvánst tartalmazó vakcina készítmény |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| EA201391788A1 (ru) | 2007-06-26 | 2014-08-29 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| SG182957A1 (en) | 2007-06-27 | 2012-08-30 | Novartis Ag | Low-additive influenza vaccines |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| DK2195466T3 (da) | 2007-10-01 | 2013-01-14 | Longhorn Vaccines & Diagnostics Llc | Fremgangsmåde til opbevaring af biologiske prøver |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| CA2709927C (en) | 2007-12-21 | 2017-05-16 | Novartis Ag | Mutant forms of streptolysin o |
| BRPI0821532A2 (pt) * | 2007-12-24 | 2015-06-16 | Id Biomedical Corp Quebec | Antígenos de rsv recombinantes |
| RU2475496C2 (ru) | 2008-02-21 | 2013-02-20 | Новартис Аг | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
| US9511131B2 (en) | 2008-03-10 | 2016-12-06 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| CN101998990B (zh) | 2008-03-18 | 2013-11-27 | 诺华股份有限公司 | 流感病毒疫苗抗原制备方法的改进 |
| CA2725329C (en) | 2008-05-23 | 2013-10-01 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| ES2565846T3 (es) * | 2008-05-26 | 2016-04-07 | Cadila Healthcare Limited | Vacuna combinada contra el sarampión-papiloma humano |
| US9114098B2 (en) | 2008-06-04 | 2015-08-25 | The Chemo-Sero-Therapeutic Research Institute | Method for using inactivated Japanese encephalitis virus particles as adjuvant |
| EP2324062A4 (en) * | 2008-07-18 | 2012-06-06 | Id Biomedical Corp Quebec | CHIMERIC RSV POLYPEPTIDE ANTIGEN |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| RU2495049C2 (ru) | 2008-12-09 | 2013-10-10 | Пфайзер Вэксинс ЭлЭлСи | Вакцина против пептида ch3 ige |
| EP3173097A3 (en) | 2009-02-10 | 2017-07-12 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
| AU2010215595A1 (en) * | 2009-02-17 | 2011-08-25 | Glaxosmithkline Biologicals S.A. | Inactivated dengue virus vaccine with aluminium-free adjuvant |
| US20120058149A1 (en) * | 2009-03-05 | 2012-03-08 | Mccloskey Jenny Colleen | Treatment of infection |
| RU2011140508A (ru) | 2009-03-06 | 2013-04-20 | Новартис Аг | Антигены хламидии |
| ES2565377T3 (es) | 2009-04-14 | 2016-04-04 | Glaxosmithkline Biologicals Sa | Composiciones para inmunización contra Staphylococcus aureus |
| US8574589B2 (en) | 2009-05-11 | 2013-11-05 | Novartis Ag | Antigen purification process for pertactin antigen |
| PL2437753T3 (pl) | 2009-06-05 | 2017-03-31 | Infectious Disease Research Institute | Syntetyczne adiuwanty glukopiranozylolipidowe oraz zawierające je kompozycje szczepionek |
| CN102802665B (zh) | 2009-06-15 | 2015-11-25 | 新加坡国立大学 | 流感疫苗、组合物及使用方法 |
| CA2765511C (en) * | 2009-06-16 | 2015-05-12 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| WO2010149745A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
| JP5796011B2 (ja) | 2009-06-24 | 2015-10-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| US20120087937A1 (en) | 2009-06-25 | 2012-04-12 | Brigitte Desiree Alberte Colau | Novel compositions |
| WO2011004263A2 (en) | 2009-07-07 | 2011-01-13 | Novartis Ag | Conserved escherichia coli immunogens |
| CN105214080A (zh) | 2009-07-15 | 2016-01-06 | 诺华股份有限公司 | Rsv f蛋白组合物和其制作方法 |
| PL2464658T3 (pl) | 2009-07-16 | 2015-03-31 | Novartis Ag | Immunogeny z Escherichia coli o zniesionej toksyczności |
| RU2518291C2 (ru) | 2009-07-30 | 2014-06-10 | Пфайзер Вэксинс ЭлЭлСи | Антигенные tau-пептиды и их применения |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| KR20120059572A (ko) * | 2009-08-26 | 2012-06-08 | 셀렉타 바이오사이언시즈, 인크. | Ｔ－세포 도움을 유도하는 조성물 |
| BR112012004275A2 (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp |
| KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Ｐｃｓｋ９ 백신 |
| CN102596254B (zh) | 2009-09-30 | 2016-10-19 | 诺华股份有限公司 | 金黄色葡萄球菌5型和8型荚膜多糖的偶联 |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| CN102917730A (zh) | 2009-10-27 | 2013-02-06 | 诺华有限公司 | 修饰的脑膜炎球菌fHBP多肽 |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| SG181628A1 (en) | 2009-12-22 | 2012-07-30 | Celldex Therapeutics Inc | Vaccine compositions |
| CN102869372B (zh) | 2010-01-27 | 2016-01-20 | 葛兰素史密丝克莱恩生物有限公司 | 经修饰的结核抗原 |
| CN102834410B (zh) | 2010-03-30 | 2016-10-05 | 奥克兰儿童医院及研究中心 | 改性的h因子结合蛋白（fhbp）及其使用方法 |
| US9597326B2 (en) | 2010-04-13 | 2017-03-21 | Glaxosmithkline Biologicals Sa | Benzonapthyridine compositions and uses thereof |
| EP2575886A4 (en) | 2010-05-26 | 2015-02-25 | Selecta Biosciences Inc | NANOVECTOR COMPOSITIONS COMPRISING A DECOUPLED ADJUVANT |
| WO2011148382A1 (en) | 2010-05-28 | 2011-12-01 | Biological E Limited | An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol. |
| CN102933267B (zh) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | 交互式混合异步计算机游戏基础结构 |
| WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
| WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| AU2011276328C1 (en) | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| CN102441162B (zh) * | 2010-10-04 | 2018-07-24 | 免疫产品美国股份有限公司 | 结核病的治疗和预防 |
| US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| HUE043879T2 (hu) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | RSV-immunizálási rend |
| EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
| JP5798356B2 (ja) * | 2011-04-06 | 2015-10-21 | 一般財団法人化学及血清療法研究所 | 新規インフルエンザワクチン安定化剤 |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| LT2707385T (lt) | 2011-05-13 | 2017-12-11 | Glaxosmithkline Biologicals Sa | Iš anksto sulieti rsv f antigenai |
| JP6109165B2 (ja) | 2011-07-01 | 2017-04-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ヘルペスウイルスワクチンおよび使用方法 |
| WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| FR2977800B1 (fr) * | 2011-07-13 | 2014-03-14 | Sanofi Pasteur | Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium |
| US20130039954A1 (en) | 2011-07-29 | 2013-02-14 | Selecta Biosciences, Inc. | Control of antibody responses to synthetic nanocarriers |
| EP2747779A4 (en) | 2011-08-22 | 2015-04-08 | Nanobio Corp | HERPES SIMPLEX VIRUS VACCINE NANOEMULSION |
| BR112014005406A2 (pt) | 2011-09-09 | 2017-03-28 | Nanobio Corp | composição de vacina e respectivo uso |
| EP2755684A1 (en) | 2011-09-12 | 2014-07-23 | Jonathan Norden Weber | Methods and compositions for raising an immune response to hiv |
| EP2793939A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Stable compositions for immunising against staphylococcus aureus |
| EP2806890A4 (en) | 2012-01-26 | 2015-09-02 | Longhorn Vaccines & Diagnostics Llc | COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES |
| WO2013139744A1 (en) | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
| WO2013158673A1 (en) * | 2012-04-16 | 2013-10-24 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
| EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
| EP2852414B9 (en) | 2012-05-22 | 2020-12-09 | GlaxoSmithKline Biologicals SA | Meningococcus serogroup x conjugate |
| EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
| WO2014033191A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| WO2014033190A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| JP2015532276A (ja) | 2012-10-02 | 2015-11-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 非直鎖状糖コンジュゲート |
| MX2015002483A (es) | 2012-10-03 | 2016-01-08 | Glaxosmithkline Biolog Sa | Composiciones inmunogenicas. |
| CA2888293C (en) * | 2012-10-19 | 2018-11-06 | Hal Allergy Holding B.V. | Compositions for immunotherapy |
| RS56886B1 (sr) | 2012-11-30 | 2018-04-30 | Glaxosmithkline Biologicals Sa | Antigeni pseudomonasa i kombinacije antigena |
| EA032326B1 (ru) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Монотерапия gla для применения в лечении рака |
| CA2909586C (en) | 2013-05-15 | 2021-08-31 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20220080201A (ko) | 2014-01-21 | 2022-06-14 | 화이자 인코포레이티드 | 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| CN106103469B (zh) | 2014-03-26 | 2020-11-27 | 葛兰素史密丝克莱恩生物有限公司 | 突变型葡萄球菌抗原 |
| JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
| AU2015292615B2 (en) | 2014-07-23 | 2019-10-24 | Children's Hospital & Research Center At Oakland | Factor H binding protein variants and methods of use thereof |
| HUE062499T2 (hu) | 2015-01-15 | 2023-11-28 | Pfizer | Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
| AU2016271857B2 (en) | 2015-06-03 | 2020-05-28 | Affiris Ag | IL-23-P19 vaccines |
| CN107849119A (zh) | 2015-07-07 | 2018-03-27 | 阿费里斯股份公司 | 用于治疗和预防IgE介导的疾病的疫苗 |
| TWI720448B (zh) | 2015-07-21 | 2021-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| JP7223989B2 (ja) | 2015-08-25 | 2023-02-17 | アグラワル，バビタ | 免疫調節組成物およびその使用方法 |
| EP4491735A3 (en) | 2015-10-08 | 2025-04-16 | The Governors of the University of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| WO2017136837A1 (en) | 2016-02-06 | 2017-08-10 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| WO2018013797A1 (en) | 2016-07-13 | 2018-01-18 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| JP7274214B2 (ja) | 2016-08-02 | 2023-05-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫応答を調節するための生体材料 |
| US11466292B2 (en) | 2016-09-29 | 2022-10-11 | Glaxosmithkline Biologicals Sa | Compositions and methods of treatment |
| WO2018097642A1 (ko) * | 2016-11-25 | 2018-05-31 | 재단법인 목암생명과학연구소 | 바리셀라 조스터 바이러스 백신 |
| EP3545972A4 (en) | 2016-11-25 | 2020-05-13 | Mogam Institute For Biomedical Research | VARICELLA AND ZONA VIRUS VACCINE |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| CN107537035A (zh) * | 2017-08-30 | 2018-01-05 | 北京恩元华生物科技有限公司 | 复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用 |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| TW202003023A (zh) | 2018-03-12 | 2020-01-16 | 美商詹森藥物公司 | 針對尿路感染之疫苗 |
| EP3807298A1 (en) | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
| CA3107077A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| IL282753B2 (en) | 2018-11-06 | 2025-04-01 | Glaxosmithkline Biologicals Sa | Immunogenic compounds |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| WO2020128012A1 (en) | 2018-12-21 | 2020-06-25 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| BR112021017584A2 (pt) | 2019-03-05 | 2021-11-09 | Glaxosmithkline Biologicals Sa | Regime e composições de imunização contra hepatite b |
| BR112021018236A2 (pt) | 2019-03-18 | 2021-11-23 | Glaxosmithkline Biologicals Sa | Bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinante |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| JP2022528158A (ja) | 2019-04-10 | 2022-06-08 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用 |
| CN112138155B (zh) * | 2019-06-28 | 2022-04-12 | 怡道生物科技(苏州)有限公司 | 一种复合佐剂系统及制备该佐剂的方法 |
| WO2021067785A1 (en) | 2019-10-02 | 2021-04-08 | Janssen Vaccines & Prevention B.V | Staphylococcus peptides and methods of use |
| KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
| PL4090363T3 (pl) | 2020-01-16 | 2024-11-25 | Janssen Pharmaceuticals, Inc. | Mutant fimh, jego kompozycje i jego zastosowanie |
| CA3165957A1 (en) | 2020-01-24 | 2021-07-29 | Thomas K. EQUELS | Methods, compositions, and vaccines for treating a virus infection |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| CA3171864A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
| JP2023514697A (ja) | 2020-02-23 | 2023-04-07 | ファイザー・インク | 大腸菌組成物およびその方法 |
| EP4114848A4 (en) | 2020-02-26 | 2024-04-03 | Versitech Limited | PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION |
| CN111920946B (zh) * | 2020-08-07 | 2021-05-28 | 合肥诺为尔基因科技服务有限公司 | 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统及基于其的SARS-CoV-2亚单位疫苗 |
| EP4213870A1 (en) | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| KR20230091978A (ko) | 2020-10-20 | 2023-06-23 | 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 | 면역원성 항원 |
| PE20231934A1 (es) | 2020-10-27 | 2023-12-01 | Pfizer | Composiciones de escherichia coli y metodos de las mismas |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| MX2023008251A (es) | 2021-01-12 | 2023-07-26 | Janssen Pharmaceuticals Inc | Mutantes de fimh, composiciones con estos y uso de estos. |
| WO2022171681A1 (en) | 2021-02-11 | 2022-08-18 | Glaxosmithkline Biologicals Sa | Hpv vaccine manufacture |
| IT202100003470A1 (it) | 2021-02-16 | 2022-08-16 | Fond Toscana Life Sciences | Vaccines against sars-cov-2 |
| KR20230147075A (ko) | 2021-02-19 | 2023-10-20 | 사노피 파스퇴르 인크 | 수막구균 b 재조합 백신 |
| CN115120713A (zh) * | 2021-03-25 | 2022-09-30 | 四川大学 | 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途 |
| US12290563B2 (en) | 2021-04-01 | 2025-05-06 | Janssen Pharmaceuticals, Inc. | Production of E. coli 018 bioconjugates |
| WO2022234483A1 (en) | 2021-05-04 | 2022-11-10 | King Abdullah University Of Science And Technology | Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof |
| EP4346892A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20220387576A1 (en) | 2021-05-28 | 2022-12-08 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2022391752A1 (en) | 2021-11-18 | 2024-06-13 | Matrivax, Inc. | Immunogenic fusion protein compositions and methods of use thereof |
| KR20240128715A (ko) | 2022-01-13 | 2024-08-26 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| US20250163484A1 (en) | 2022-02-25 | 2025-05-22 | Pfizer Inc. | Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides |
| KR20250008122A (ko) | 2022-05-11 | 2025-01-14 | 화이자 인코포레이티드 | 보존제를 갖는 백신 제형의 제조 방법 |
| KR20250038747A (ko) | 2022-07-22 | 2025-03-19 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도 |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| CN120456919A (zh) | 2022-12-19 | 2025-08-08 | 葛兰素史克生物有限公司 | 乙型肝炎组合物 |
| EP4661911A1 (en) | 2023-02-10 | 2025-12-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121038808A (zh) | 2023-03-30 | 2025-11-28 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| KR20250169621A (ko) | 2023-04-14 | 2025-12-03 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| WO2025028658A1 (ja) * | 2023-08-03 | 2025-02-06 | 国立大学法人東京農工大学 | 免疫増強剤及び免疫増強方法並びにタンパク質の凝集体及び／又は会合体の製造方法 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186660A1 (en) | 2024-03-05 | 2025-09-12 | Fondazione Toscana Life Sciences | Mutated spike proteins as vaccines against sars-cov-2 |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0002920B1 (en) | 1977-12-20 | 1982-01-13 | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and | Liquid crystal displays |
| DE2837342A1 (de) | 1978-08-26 | 1980-03-06 | Henkel Kgaa | Verfahren zur herstellung von hefeautolysat |
| DE3380307D1 (en) | 1982-12-23 | 1989-09-07 | Procter & Gamble | Ethoxylated amine polymers having clay soil removal/anti-redeposition properties useful in detergent compositions |
| FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
| US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
| AP56A (en) | 1987-01-30 | 1989-09-26 | Smithkline Biologicals S A | Hepatitis B virus surface antigens and hybrid antigehs containing them. |
| AU614755B2 (en) | 1987-06-05 | 1991-09-12 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Autocrine motility factors in cancer diagnosis and management |
| EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
| ATE105858T1 (de) | 1987-07-17 | 1994-06-15 | Rhein Biotech Ges Fuer Biotech | Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung. |
| JPH085804B2 (ja) | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | Ａ型及びｂ型肝炎混合アジュバントワクチン |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| DE3834729A1 (de) * | 1988-10-12 | 1990-04-19 | Behringwerke Ag | Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen |
| ATE159031T1 (de) | 1989-07-25 | 1997-10-15 | Smithkline Biolog | Antigene sowie verfahren zu deren herstellung |
| GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
| GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| CA2067003A1 (en) | 1991-04-29 | 1992-10-30 | Peter J. Kniskern | Hbsag escape mutant vaccine |
| ES2129461T3 (es) | 1991-11-16 | 1999-06-16 | Smithkline Beecham Biolog | Proteina hibrida entre cs de plasmodium y hbsag. |
| MY111880A (en) | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
| US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| EP2156845A1 (en) | 1992-05-23 | 2010-02-24 | GlaxoSmithKline Biologicals SA | Combined vaccines comprising hepatitis B surface antigen and other antigens |
| DE69334192T2 (de) * | 1992-06-25 | 2008-12-04 | Georgetown University | Papillomavirus vakzine |
| AU661404B2 (en) * | 1992-06-25 | 1995-07-20 | Smithkline Beecham Biologicals (Sa) | Vaccine composition containing adjuvants |
| US5618536A (en) | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
| NZ263538A (en) | 1993-03-23 | 1996-10-28 | Smithkline Beecham Biolog | Vaccine compositions of 3-o-deacylated monophosphoryl lipid a |
| CA2163550A1 (en) * | 1993-05-25 | 1994-12-08 | Gerald E. Hancock | Adjuvants for vaccines against respiratory syncytial virus |
| DE4322107A1 (de) | 1993-07-02 | 1995-01-12 | Siemens Ag | Einrichtung zum Auffangen und Kühlen von Kernschmelze |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP0757717B1 (en) | 1994-05-16 | 2006-05-31 | Merck & Co. Inc. | Papillomavirus vaccines |
| DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
| US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| DE122007000093I1 (de) | 1994-10-07 | 2008-03-27 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| US6488934B1 (en) * | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| KR0184779B1 (ko) * | 1995-04-13 | 1999-04-01 | 성재갑 | 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형 |
| GB9620795D0 (en) * | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6251405B1 (en) | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
| IL122588A (en) * | 1995-06-23 | 2001-12-23 | Smithkline Beecham Biolog | A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5733011A (en) * | 1997-02-06 | 1998-03-31 | Richard A. Young | Multiple position tool caddy seat |
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| JP4510283B2 (ja) | 1998-03-09 | 2010-07-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 併合ワクチン組成物 |
| GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| GB9806666D0 (en) | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| US6025468A (en) * | 1998-06-20 | 2000-02-15 | United Biomedical, Inc. | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| US6602697B1 (en) * | 1998-08-14 | 2003-08-05 | Merck & Co., Inc. | Process for purifying human papillomavirus virus-like particles |
| US6692752B1 (en) * | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
| GB9819898D0 (en) | 1998-09-11 | 1998-11-04 | Smithkline Beecham Plc | New vaccine and method of use |
| ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| AUPP765398A0 (en) * | 1998-12-11 | 1999-01-14 | University Of Queensland, The | Treatment of papillomavirus infections |
| WO2001011027A1 (es) | 1999-08-06 | 2001-02-15 | Glaxo Wellcome, S.A. | Nueva proteina |
| GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6908613B2 (en) | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| GB0110431D0 (en) | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| PL215257B1 (pl) * | 2002-12-20 | 2013-11-29 | Glaxosmithkline Biolog Sa | Zastosowanie kompozycji zawierajacej VLP HPV 16 i HPV 18 oraz kompozycja szczepionkowa |
| US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| WO2005025594A1 (en) | 2003-09-10 | 2005-03-24 | S-Cell Biosciences, Inc. | Method to enhance hematopoiesis |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
-
1999
- 1999-10-08 ES ES99970607T patent/ES2284287T3/es not_active Expired - Lifetime
- 1999-10-08 PL PL348121A patent/PL201482B1/pl unknown
- 1999-10-08 SI SI9930966T patent/SI1126876T1/sl unknown
- 1999-10-08 CN CNB2004100694428A patent/CN100406060C/zh not_active Expired - Lifetime
- 1999-10-08 DE DE122007000087C patent/DE122007000087I1/de active Pending
- 1999-10-08 CA CA2347099A patent/CA2347099C/en not_active Expired - Lifetime
- 1999-10-08 EP EP05077501A patent/EP1666060A1/en not_active Withdrawn
- 1999-10-08 AT AT99970607T patent/ATE357252T1/de active
- 1999-10-08 DE DE69935606.7T patent/DE69935606T9/de active Active
- 1999-10-08 KR KR1020017004793A patent/KR100629028B1/ko not_active Expired - Lifetime
- 1999-10-08 EP EP07100777A patent/EP1797896A1/en not_active Withdrawn
- 1999-10-08 BR BRPI9915545A patent/BRPI9915545B8/pt not_active IP Right Cessation
- 1999-10-08 HK HK02100151.3A patent/HK1038695B/en not_active IP Right Cessation
- 1999-10-08 JP JP2000576878A patent/JP2003519084A/ja not_active Withdrawn
- 1999-10-08 WO PCT/EP1999/007764 patent/WO2000023105A2/en not_active Ceased
- 1999-10-08 CN CNB998143413A patent/CN100558401C/zh not_active Expired - Lifetime
- 1999-10-08 CZ CZ20011341A patent/CZ301212B6/cs not_active IP Right Cessation
- 1999-10-08 EP EP05076368A patent/EP1588714A2/en not_active Withdrawn
- 1999-10-08 NZ NZ511113A patent/NZ511113A/xx not_active IP Right Cessation
- 1999-10-08 IL IL14239599A patent/IL142395A0/xx active IP Right Grant
- 1999-10-08 US US09/807,657 patent/US7357936B1/en not_active Expired - Fee Related
- 1999-10-08 TR TR2001/01055T patent/TR200101055T2/xx unknown
- 1999-10-08 EP EP10176856A patent/EP2266604A3/en not_active Withdrawn
- 1999-10-08 DK DK99970607T patent/DK1126876T3/da active
- 1999-10-08 CA CA2773698A patent/CA2773698C/en not_active Expired - Lifetime
- 1999-10-08 HU HU0203091A patent/HU228473B1/hu active Protection Beyond IP Right Term
- 1999-10-08 AU AU11518/00A patent/AU750587B2/en not_active Expired
- 1999-10-08 CN CN2009101731658A patent/CN101926993B/zh not_active Expired - Lifetime
- 1999-10-08 PT PT99970607T patent/PT1126876E/pt unknown
- 1999-10-08 EP EP99970607A patent/EP1126876B1/en not_active Expired - Lifetime
- 1999-10-14 MY MYPI99004448A patent/MY124689A/en unknown
- 1999-10-15 TW TW088117873A patent/TW586936B/zh not_active IP Right Cessation
- 1999-10-15 CO CO99065652A patent/CO5210894A1/es active IP Right Grant
- 1999-10-15 AR ARP990105237A patent/AR020836A1/es active IP Right Grant
-
2001
- 2001-04-03 IL IL142395A patent/IL142395A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011801A patent/NO336250B1/no not_active IP Right Cessation
-
2007
- 2007-05-16 CY CY20071100661T patent/CY1106596T1/el unknown
- 2007-07-18 JP JP2007187001A patent/JP5563189B2/ja not_active Expired - Lifetime
- 2007-11-26 CY CY200700032C patent/CY2007032I1/el unknown
- 2007-12-14 NL NL300311C patent/NL300311I2/nl unknown
- 2007-12-14 LU LU91389C patent/LU91389I2/fr unknown
- 2007-12-14 FR FR07C0064C patent/FR07C0064I1/fr active Active
-
2008
- 2008-02-28 US US11/945,493 patent/US8628784B2/en not_active Expired - Fee Related
-
2012
- 2012-03-08 JP JP2012051129A patent/JP5667107B2/ja not_active Expired - Lifetime
-
2013
- 2013-09-09 HU HUS1300050C patent/HUS1300050I1/hu unknown
- 2013-12-19 US US14/134,388 patent/US9623114B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW586936B (en) | Adjuvant composition, vaccine composition, process for manufacture thereof and kit comprising same | |
| NZ253137A (en) | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. | |
| HK1108111A (en) | Adjuvant systems and vaccines | |
| MXPA01003737A (en) | Adjuvant systems and vaccines | |
| HK1084579A (en) | Adjuvant systems and vaccines | |
| HK1092707A (en) | Adjuvant systems and vaccines | |
| HK1145802A (en) | Adjuvant systems and vaccines | |
| ZA200102954B (en) | Adjuvant systems and vaccines. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |